Get the Stockscreener App
5.74
0.17%
0.010
After Hours:
5.74
Trisalus Life Sciences Inc stock is traded at $5.74, with a volume of 15,582.
It is up +0.17% in the last 24 hours and up +11.46% over the past month.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of innovative drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product lines Pressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.
See More
Previous Close:
$5.73
Open:
$5.73
24h Volume:
15,582
Relative Volume:
0.33
Market Cap:
$179.11M
Revenue:
$15.33M
Net Income/Loss:
$-40.19M
P/E Ratio:
-3.2759
EPS:
-1.7522
Net Cash Flow:
-
1W Performance:
+3.42%
1M Performance:
+11.46%
6M Performance:
+35.06%
1Y Performance:
-40.95%
1-Day Range:
$5.262
$5.80
1-Week Range:
$5.2282
$5.80
52-Week Range:
$3.50
$10.24
Trisalus Life Sciences Inc Stock (TLSI) Company Profile
Name
Trisalus Life Sciences Inc
Sector
Industry
Phone
415 336 8917
Address
6272 WEST 91ST AVENUE, WESTMINSTER
Compare TLSI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TLSI
Trisalus Life Sciences Inc
|
5.74 | 179.11M | 15.33M | -40.19M | 0 | -1.7522 |
|
ABT
Abbott Laboratories
|
130.98 | 221.92B | 41.95B | 13.40B | 6.35B | 7.65 |
|
BSX
Boston Scientific Corp
|
95.12 | 139.43B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
346.50 | 134.90B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
82.60 | 108.02B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
71.53 | 40.93B | 5.72B | 4.17B | 259.90M | 6.97 |
Trisalus Life Sciences Inc Stock (TLSI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-13-25 | Initiated | Lake Street | Buy |
| Dec-17-24 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-11-24 | Initiated | ROTH MKM | Buy |
| Oct-25-24 | Initiated | Northland Capital | Outperform |
| Sep-16-24 | Initiated | Oppenheimer | Outperform |
| May-30-24 | Initiated | Canaccord Genuity | Buy |
View All
Trisalus Life Sciences Inc Stock (TLSI) Latest News
TriSalus Life Sciences, Inc. SEC 10-K Report - TradingView
TriSalus Life Sciences, Inc. (TLSI) Soars 6.6%: Is Further Upside Left in the Stock? - Nasdaq
Uveal Neoplasms Treatment Market Size in 7MM is expected to grow - openPR.com
TriSalus Life Sciences (TLSI) Expected to Announce Quarterly Earnings on Monday - Defense World
TriSalus Life Sciences, Inc. (TLSI) Reports Q4 Loss, Tops Revenue Estimates - MSN
TriSalus Life Sciences Reports Strong Growth Amid Challenges - MSN
Canaccord Genuity Group Reiterates Buy Rating for TriSalus Life Sciences (NASDAQ:TLSI) - Defense World
TriSalus Life Sciences: Optimistic Guidance For 2025, But There Are Still Risks - Seeking Alpha
TriSalus Life Sciences’ (TLSI) “Buy” Rating Reiterated at Canaccord Genuity Group - The AM Reporter
Earnings call transcript: TriSalus Life Sciences Q4 2024 sees 44% revenue growth - Investing.com India
TriSalus Life Sciences’ Q4 Loss Exceeds Projections, Revenue Tops Estimates – Retail Stays Pessimistic - Asianet Newsable
Trisalus outlines 50% revenue growth target for 2025 driven by TriNav expansion and new market penetration - MSN
TriSalus Life Sciences Reports Strong 2024 Growth - TipRanks
Earnings call transcript: TriSalus Life Sciences Q4 2024 sees 44% revenue growth By Investing.com - Investing.com South Africa
TriSalus Life Sciences Confirms Positive Outlook For FY25Update - Nasdaq
TriSalus Life Sciences Inc Reports Q4 Revenue of $8.3M, Exceedin - GuruFocus
TriSalus Life Sciences, Inc. Q4 Loss Decreases, But Misses Estimates - Nasdaq
TRISALUS LIFE SCIENCES Earnings Results: $TLSI Reports Quarterly Earnings - Nasdaq
TriSalus Life Sciences Reports Q4 and Full Year 2024 Financial Results and Provides Business Update - Marketscreener.com
Examining the Future: TriSalus Life Sciences's Earnings Outlook - Benzinga
TriSalus Life Sciences Announces New CMS HCPCS Code for TriNav® Infusion System Mapping - Marketscreener.com
Medicare Approves $11K+ Reimbursement for TriNav Cancer Treatment SystemMajor Win for Hospitals - Stock Titan
TRISALUS LIFE SCIENCES Earnings Preview: Recent $TLSI Insider Trading, Hedge Fund Activity, and More - Nasdaq
TriSalus Announces Journal of Vascular and Interventional Radiology Publication of Data that Demonstrate Improved Therapeutic Delivery of Glass Microspheres to Solid Tumors With PEDD™ Method via the TriNav® Infusion System - Business Wire
TriSalus Life Sciences (TLSI) Projected to Post Earnings on Thursday - Defense World
TriSalus Life Sciences Announces CMS Reimbursement for the TriNav® Infusion System via Assignment of a New Technology Healthcare Common Procedure Coding System (HCPCS) Code - Business Wire
TriSalus Life Sciences (NASDAQ:TLSIW) Stock Price Down 10.7% – Here’s What Happened - Defense World
Can This Revolutionary Liver Cancer Treatment Double Drug Effectiveness? New Study Shows Remarkable Results - StockTitan
Short Interest in TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Expands By 75.3% - Defense World
TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Receives Average Recommendation of "Buy" from Analysts - MarketBeat
TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Receives Average Recommendation of “Buy” from Analysts - Defense World
TriSalus Life Sciences announces executive departure By Investing.com - Investing.com South Africa
TriSalus Life Sciences announces executive departure - Investing.com India
3 Stocks With Robust Growth Outlooks Insiders Are Buying - MSN
Trisalus Life Sciences CFO buys $33,900 in common stock - MSN
Dated alert on Trisalus Life Sciences entering credit agreement withdrawn -February 19, 2025 at 08:04 am EST - Marketscreener.com
TriSalus Life Sciences (NASDAQ:TLSI) Now Covered by Analysts at Lake Street Capital - MarketBeat
TriSalus Life Sciences (NASDAQ:TLSI) Coverage Initiated at Lake Street Capital - Defense World
Lake Street Initiates Coverage of TriSalus Life Sciences (TLSI) with Buy Recommendation - Nasdaq
TriSalus Life Sciences, Inc. (NASDAQ:TLSI) CFO Buys $33,900.00 in Stock - MarketBeat
Financial Comparison: TriSalus Life Sciences (NASDAQ:TLSI) versus Tenon Medical (NASDAQ:TNON) - Defense World
Trisalus Life Sciences Inc Stock (TLSI) Financials Data
Revenue
Net Income
Cash Flow
EPS
Trisalus Life Sciences Inc Stock (TLSI) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Szela Mary T | CEO AND PRESIDENT |
Jan 30 '25 |
Buy |
5.28 |
5,010 |
26,453 |
444,259 |
| Szela Mary T | CEO AND PRESIDENT |
Jan 29 '25 |
Buy |
5.03 |
5,030 |
25,301 |
439,249 |
| Szela Mary T | CEO AND PRESIDENT |
Jan 27 '25 |
Buy |
5.42 |
4,826 |
26,157 |
429,503 |
| Szela Mary T | CEO AND PRESIDENT |
Jan 28 '25 |
Buy |
5.12 |
4,716 |
24,146 |
434,219 |
| Murphy Sean | Chief Manuf, Strategy&Bus Dev. |
Jan 27 '25 |
Buy |
5.31 |
15,000 |
79,650 |
182,732 |
| Murphy Sean | Chief Manuf, Strategy&Bus Dev. |
Jan 28 '25 |
Buy |
5.17 |
15,000 |
77,550 |
197,732 |
| Young James Emmett | Chief Financial Officer |
Jan 27 '25 |
Buy |
5.40 |
24,000 |
129,600 |
24,000 |
| Cox Bryan F. | CHIEF SCIENTIFIC & MANUFACT. |
Oct 05 '24 |
Sale |
4.44 |
314 |
1,394 |
86,382 |
| Frankenius Equity AB | 10% Owner |
Dec 17 '24 |
Buy |
3.97 |
62,972 |
249,999 |
6,230,748 |
| Desai Arjun JJ | Director |
Dec 10 '24 |
Sale |
3.69 |
30,000 |
110,700 |
247,127 |
1.01%
0.46%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):